CN102164638A - 组蛋白脱乙酰酶抑制剂在治疗费城-阴性骨髓增生综合征中的用途 - Google Patents

组蛋白脱乙酰酶抑制剂在治疗费城-阴性骨髓增生综合征中的用途 Download PDF

Info

Publication number
CN102164638A
CN102164638A CN2009801382462A CN200980138246A CN102164638A CN 102164638 A CN102164638 A CN 102164638A CN 2009801382462 A CN2009801382462 A CN 2009801382462A CN 200980138246 A CN200980138246 A CN 200980138246A CN 102164638 A CN102164638 A CN 102164638A
Authority
CN
China
Prior art keywords
hydroxycarbamoyl
diethyl
phenylcarbamoyloxymethyl
philadelphia
naphthalene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801382462A
Other languages
English (en)
Chinese (zh)
Inventor
T·奥尔多尼
P·马斯卡尼
A伦巴迪
T·巴尔布伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of CN102164638A publication Critical patent/CN102164638A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2009801382462A 2008-09-29 2009-09-21 组蛋白脱乙酰酶抑制剂在治疗费城-阴性骨髓增生综合征中的用途 Pending CN102164638A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI2008A001720 2008-09-29
ITMI2008A001720A IT1392908B1 (it) 2008-09-29 2008-09-29 Uso degli inibitori delle istone-deacetilasi per la cura di sindromi mieloproliferative philadelphia-negative
US19328308P 2008-11-13 2008-11-13
US61/193,283 2008-11-13
PCT/EP2009/062214 WO2010034693A1 (en) 2008-09-29 2009-09-21 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Publications (1)

Publication Number Publication Date
CN102164638A true CN102164638A (zh) 2011-08-24

Family

ID=40810309

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801382462A Pending CN102164638A (zh) 2008-09-29 2009-09-21 组蛋白脱乙酰酶抑制剂在治疗费城-阴性骨髓增生综合征中的用途

Country Status (17)

Country Link
US (4) US20110294892A1 (https=)
EP (1) EP2344253B1 (https=)
JP (1) JP2012504112A (https=)
KR (3) KR20110069075A (https=)
CN (1) CN102164638A (https=)
BR (1) BRPI0913699A2 (https=)
CA (1) CA2738081C (https=)
CY (1) CY1115255T1 (https=)
DK (1) DK2344253T3 (https=)
ES (1) ES2478827T3 (https=)
HR (1) HRP20140499T1 (https=)
IT (1) IT1392908B1 (https=)
PL (1) PL2344253T3 (https=)
PT (1) PT2344253E (https=)
SI (1) SI2344253T1 (https=)
SM (1) SMT201400087B (https=)
WO (1) WO2010034693A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217079B2 (en) * 2010-03-26 2012-07-10 Italfarmaco Spa Method for treating Philadelphia-negative myeloproliferative syndromes
WO2015165975A1 (en) * 2014-04-29 2015-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating myeloid neoplasias
US20180127386A1 (en) 2016-10-20 2018-05-10 Forma Therapeutics, Inc. Methods using hdac11 inhibitors
US10865328B2 (en) * 2017-02-20 2020-12-15 Dow Silicones Corporation Room-temperature-curable silicone composition and electric/electronic apparatus
US11535607B2 (en) 2018-04-20 2022-12-27 Valo Health, Inc. Isoindolines as HDAC inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
ITMI20030063A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
ITMI20030064A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Uso dei derivati dell'acido idrossamico per la preparazione
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
WO2006063294A2 (en) * 2004-12-09 2006-06-15 Kalypsys, Inc. Novel inhibitors of histone deacetylase for the treatment of disease
CA2615574A1 (en) * 2005-07-29 2007-02-08 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
BRPI0619599A2 (pt) 2005-12-09 2011-10-11 Massachusetts Inst Technology método para inibir células de linhagem de tumor e para inibir o crescimento de tumores em um paciente
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2008082646A2 (en) * 2006-12-28 2008-07-10 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
V GUERINI等: "The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F", 《LEUKEMIA》 *

Also Published As

Publication number Publication date
EP2344253A1 (en) 2011-07-20
EP2344253B1 (en) 2014-04-23
CY1115255T1 (el) 2017-01-04
KR20110069075A (ko) 2011-06-22
BRPI0913699A2 (pt) 2017-06-13
HRP20140499T1 (hr) 2014-07-04
PT2344253E (pt) 2014-07-16
CA2738081A1 (en) 2010-04-01
IT1392908B1 (it) 2012-04-02
PL2344253T3 (pl) 2014-09-30
WO2010034693A1 (en) 2010-04-01
SI2344253T1 (sl) 2014-08-29
DK2344253T3 (da) 2014-06-16
US20140039059A1 (en) 2014-02-06
US20170049740A1 (en) 2017-02-23
US20210128512A1 (en) 2021-05-06
ITMI20081720A1 (it) 2010-03-30
US9522127B2 (en) 2016-12-20
JP2012504112A (ja) 2012-02-16
SMT201400087B (it) 2014-09-08
KR20160096721A (ko) 2016-08-16
US20110294892A1 (en) 2011-12-01
ES2478827T3 (es) 2014-07-23
CA2738081C (en) 2017-11-07
KR20170124640A (ko) 2017-11-10

Similar Documents

Publication Publication Date Title
Lu et al. Sertraline ameliorates inflammation in CUMS mice and inhibits TNF-α-induced inflammation in microglia cells
US20210128512A1 (en) Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
ES2410930T3 (es) Nuevos enfoques terapéuticos para tratar la enfermedad de alzheimer y trastornos relacionados mediante la modulación de la respuesta de estrés celular
US10973820B2 (en) Compounds for treatment of diseases related to DUX4 expression
JP2005525345A (ja) Ｔｒｘ媒介性疾患を処置する方法
US20200325148A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
Miao et al. Leptin modulates the expression of catabolic genes in rat nucleus pulposus cells through the mitogen‑activated protein kinase and Janus kinase 2/signal transducer and activator of transcription 3 pathways
Ochi et al. Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer‐associated fibroblast
JP2009527478A (ja) パーキンソン病の治療のための方法と組成物
Chang et al. Regulation of metastatic ability and drug resistance in pulmonary adenocarcinoma by matrix rigidity via activating c-Met and EGFR
Li et al. Dimethyl fumarate protection against collagen II degradation
He et al. Investigation for effects of iNOS on biological function of chondrocytes in rats with post-traumatic osteoarthritis.
Yamanaka et al. Map kinase c‐JUN N‐terminal kinase mediates PMMA induction of osteoclasts
US8217079B2 (en) Method for treating Philadelphia-negative myeloproliferative syndromes
JP2021187831A (ja) Ｓ−ヒドロキシクロロキンを用いたエリテマトーデスの治療
ES2239529B1 (es) Procedimiento de identificacion de los compuestos reguladores de la actividad tubulina desacetilasa de hdac6 y sus aplicaciones.
ES3028375T3 (en) 1,2-dihydroquinoline-2-ones for their use in the treatment of limb-girdle muscular dystrophy
WO2025059029A1 (en) Methods of treating vexas syndrome
Wilson et al. REPROGRAM: REsilience PROmotion with GeRoprotectors: AssessMent of biological effect. Rationale and protocol for a trial of biological effect.
ES2589169B1 (es) Uso de la pentoxifilina y de una composición farmacéutica para elaborar un medicamento para prevenir el envejecimiento prematuro en humanos
Höfer The role of the Caspase-Activated DNAse in growth behavior and tumor cell metastasis
AU2017263174A1 (en) Methods of treating diseases associated with ILC3 cells
Guo et al. Mechanism of Activation of AMPK/P53-CyPD Signalling Pathway in Inhibiting Osteoblast Apoptosis Induced by Dexamethasone.
CN119732948A (zh) 一种抗恶性神经胶质瘤药物组合物及应用
Ferreira The role of post-translational modifications on STAT3 interactions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110824